Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Kevin Kotler, Broadfin Capital Increase Holding Of Progenics Pharmaceuticals, Inc. (PGNX)

Kevin Kotler is bullish on Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) and has decided to boost his fund’s investment in the stock. Kotler’s Broadfin Capital has increased its holding by 60% to a little over 8.95 million shares, as reported in a recent filing with the Securities and Exchange Commission. The fund’s current ownership of the stock gives it control over 12.9% of the total number of shares outstanding.

Kevin Kotler

Julian and Felix Baker also like Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) and have increased their investment during the first quarter of 2014. As reported in its latest 13F filing, Baker Bros. Advisors holds approximately 4.45 million shares, up 6% from the end of 2013. Paul Tudor Jones is not so optimistic, though, and has chosen to trim his fund’s stake in the company by 1% during the same period of time. Tudor Investment Corp reportedly holds 2.34 million shares of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). James Dondero is of the same opinion and has reduced his fund’s investment by 6% to a little over 1.38 million shares.

Discosure: none.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!